Opioid Use
Conditions
Brief summary
This study seeks to test standard and behavioral economic-enhanced training strategies to bolster first-time Emergency Department-initiated buprenorphine-naloxone administration among Emergency Department providers.
Detailed description
Philadelphia is experiencing a significant opioid crisis. Through this novel pilot study, critical training about opioid use disorder and medication-assisted treatment with buprenorphine-naloxone will be provided to emergency providers and changes in clinical practice will be incentivized in order to optimize treatment engagement for patients with opioid use disorder in the Emergency Department. Participants will be invited to participate in a brief in-person training session, will receive a pre- and post-session knowledge and attitude assessment, and will be invited to self-report first-time buprenorphine-naloxone Emergency Department administration within the 3 month study period. Participants will be randomized to one of two arms: standard training arm and behavioral economic enhanced arm. The standard training arm will receive the aforementioned intervention. The behavioral economic enhanced arm will additionally receive an opt-out invitation, loss-framed incentivization, and weekly tailored text message-based reminders. Endpoints of interest include retained knowledge and change in provider attitudes regarding Emergency department buprenorphine-naloxone administration and treatment following training and again at 3 months, and first-time Emergency department administration of buprenorphine-naloxone.
Interventions
BEHAVIORALTraining
The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period
BEHAVIORALBehavioral economic enhanced arm
Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
Sponsors
American College of Medical Toxicology
Blue Cross Blue Shield
University of Pennsylvania
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Residents and Advanced Practice Providers and attending clinicians working in emergency departments in Pennsylvania.
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Emergency Department initiated buprenorphine-naloxone treatment | One year | Measuring number of providers who have initiated at least one first dose of buprenorphine-naloxone |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Training Attendance | First week | Measure the number of clinicians who attend the training with the incentive. |
| Change in attitude about buprenorphine-naloxone Questionaire | Three months | The scale is not a validated tool. It is a construct to measure attitudes about buprenorphine-naloxone. It is a Likert scale 1-5, 1 being strongly disagree and 5 being strongly agree. Higher values signify more favorable outcomes. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Retained knowledge of buprenorphine-naloxone treatment Questionaire | Three months | Compare retention of knowledge and assessment from before and after the training in the two arms.The scale is not a validated tool. It is a construct of questions to measure retained knowledge about buprenorphine-naloxone initiation. The scale is a percentage of questions answered correctly. Minimum score is 0% and maximum score is 100%. Higher values signify more favorable outcomes. |
Countries
United States
Outcome results
None listed